DCR

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Retrieved on: 
Thursday, February 29, 2024

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.

Key Points: 
  • MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
  • Additionally, in October 2023, Knight received pricing approval for Minjuvi® from the Drugs Market Regulation Chamber (“CMED”).
  • “In line with Knight’s commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team in Brazil is thrilled to make Minjuvi® available to health care professionals and centers, improving DLBCL patient care in the country,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Retrieved on: 
Tuesday, February 27, 2024

REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN).

Key Points: 
  • The Phase 1/2 dose escalation study (NCT04474470) evaluated NT219 as a monotherapy in various indications and in combination with cetuximab in the treatment of R/M SCCHN and colorectal cancer.
  • As of cut-off date of January 25, 2024:
    Seventeen patients with R/M SCCHN were enrolled in the combination arm of NT219 + cetuximab.
  • The median number of prior lines of therapy was 2 and 94% of the patients received prior immunotherapy.
  • “We were encouraged to see anti-tumor activity in HPV negative patients,” said Dr. Michael Schickler, Purple Biotech’s Head of Clinical and Regulatory Affairs.

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

Retrieved on: 
Wednesday, March 6, 2024

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive efficacy data for third-line treatment in its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive efficacy data for third-line treatment in its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).
  • “Around 60-70% of NSCLC patients do not have a targetable mutation and cannot benefit from a biomarker-targeted therapy, making it the greatest unmet medical need population in lung cancer.
  • Two third-line patients in the 180mg dose cohort did not have recorded scans at the data cutoff.
  • THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment.

FDA Grants Fast Track Designation to 9MW2821

Retrieved on: 
Tuesday, February 27, 2024

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").

Key Points: 
  • SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").
  • 9MW2821 is the world's first Nectin-4-targeting drug to disclose clinical efficacy data for the indication of EC.
  • After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells.
  • 9MW2821 is also the first to disclose preliminary clinical efficacy data for the indication of CC among drugs with the same target in the world.

Alzheimer's Research & Therapy: Linus Health Digital Clock and Recall Test Detects Early Cognitive Impairment in Over 80% of Patients Who Were Misclassified in Commonly Used Paper-Based Test

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- A proprietary cognitive assessment from Linus Health, a digital health company focused on enabling early detection of Alzheimer's and other dementias, outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and dementia and with less ethnic and racial bias, according to a peer-reviewed study recently published in the prestigious medical journal Alzheimer's Research & Therapy.

Key Points: 
  • The body of research confirms the most recent findings that the DCR outperforms a commonly used traditional cognitive test, the MMSE, in detecting early signs of cognitive impairment, and is more accurate overall in classifying mild cognitive impairment and mild dementia.
  • More than 80% of Americans are unfamiliar with mild cognitive impairment, which can be an early stage of Alzheimer's Disease, according to the Alzheimer's Association.
  • Symptoms are also not always noticeable, leading to delayed screenings and potentially greater risk to patients' brain health.
  • In contrast, the DCR was able to detect cognitive impairment in more than 80% of those the MMSE misclassified.

NIELSEN AND NEXSTAR ANNOUNCE COMPREHENSIVE AGREEMENT FOR LOCAL & NATIONAL TV MEASUREMENT SERVICES

Retrieved on: 
Wednesday, January 31, 2024

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Nielsen, a global leader in audience measurement, data and analytics, today announced a multi-year extension of an agreement with Nexstar Media Group, Inc.(NASDAQ: NXST), to provide Local and National TV measurement services across Nexstar's media businesses, including The CW Network, NewsNation, Antenna TV, and 200 owned or partner television stations in 116 local markets across the country. Under the terms of the agreement, Nielsen will continue to be a preferred Nexstar provider of currency-grade TV audience data.

Key Points: 
  • Under the terms of the agreement, Nielsen will continue to be a preferred Nexstar provider of currency-grade TV audience data.
  • Nexstar will continue to leverage a comprehensive suite of Nielsen's Local, National & Digital solutions including Over the Top (OTT) measurement, cross-media measurement via Nielsen ONE Ads, Digital Content Ratings (DCR), Digital in TV Ratings (DTVR), Scarborough, Rhiza and Grabix - which all provide important audience insights.
  • Nielsen is continuously working to evolve its measurement services to provide a comprehensive view of the fragmented viewing landscape.
  • In reaching this agreement, Nexstar, as well as all Nielsen customers, have access to Nielsen's Big Data + Panel measurement approach.

PatientPoint Becomes First Point-of-Care Publisher to Earn Media Rating Council Accreditation

Retrieved on: 
Tuesday, January 30, 2024

PatientPoint is the first Point-of-Care publisher to receive accreditation for its reported metrics by the media industry's foremost independent measurement authority.

Key Points: 
  • PatientPoint is the first Point-of-Care publisher to receive accreditation for its reported metrics by the media industry's foremost independent measurement authority.
  • PatientPoint joins some of the most recognizable names in traditional and digital media channels such as Google, Nielsen and Meta in receiving MRC accreditation for metrics supporting specific products.
  • "Receiving accreditation from the most respected media measurement authority should give sponsors full confidence in our business metrics and delivery guarantees.
  • Importantly, we believe MRC accreditation further underscores why Point of Care should be viewed as a foundational component of any life sciences brand media mix."

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024

REDWOOD CITY, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC). These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California. Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.

Key Points: 
  • These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California.
  • Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment.
  • Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.
  • Coherus plans to evaluate the combination of casdozo/toripalimab-tpzi(Coherus’ anti-PD-1 antibody)/bev in future clinical trials.

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

Retrieved on: 
Wednesday, January 17, 2024

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new interim data for its ongoing THIO-101 Phase 2 trial in non-small cell lung cancer (NSCLC) and outlined key clinical milestones for 2024.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new interim data for its ongoing THIO-101 Phase 2 trial in non-small cell lung cancer (NSCLC) and outlined key clinical milestones for 2024.
  • In the latest available data from THIO-101 (November 13, 2023), 60 patients had been dosed with THIO in sequential combination with Libtayo®.
  • The patients received either 60mg, 180mg, or 360mg of THIO per dose, and 42 had at least one post baseline assessment completed.
  • THIO is the only direct telomere targeting agent currently undergoing clinical development in the field of cancer drug discovery and treatment.